Comment
Vitamin D supplementation: bones of contention
The discovery of vitamin D as an essential nutrient for skeletal development a century ago was a major pub-lic health victory. Supplementation, whether solar or dietary, prevented the devastating e ects of rickets in chil dren. Five decades later, the molecular mechanisms of the vitamin’s active form (1,25-dihydroxyvitamin D) and its receptor (vitamin D receptor [VDR]), were elucidated, and subsequently clinical investigators linked vitamin D de ciency or insu ciency with osteoporosis. This nding seemed logical because osteomalacia (ie, the softening of bone in adults due to impaired mineralisation) can cause fractures and often coexists histologically with osteoporosis. Slowly, vitamin D supplementation became established for prevention of osteoporosis. But, as shown in a meta-analysis in The Lancet,1 the story is more complex, both from an epidemiological and mechanistic perspective.
Ian Reid and colleagues1 did a systematic review of the e ects of vitamin D supplements on bone mineral density that included 23 randomised controlled trials encompassing more than 4000 participants, with a mean age of 59 years. The authors found that vitamin D supplementation for 2 years resulted in no change in bone mineral density at four major skeletal sites (spine, total hip, radius, and total body), with a signi cant increase (0·8%, 95% CI 0·2–1·4) only at the femoral neck. Surprisingly, any bene t reported in bone mineral density was independent of calcium supplementation, baseline concentration of 25-hydroxyvitamin D, duration of treatment, or age. The investigators conclude that widespread vitamin D prophylaxis in healthy community dwelling adults to prevent osteoporosis is unwarranted.How can these surprising ndings be reconciled with clinical practice and public health strategies to prevent osteoporosis? First, bone mineral density was

the primary outcome in the present analysis and is widely used as a surrogate measure of fracture risk. However, changes of bone mineral density in this age group are a modest predictor of subsequent fractures.2,3 Even with bisphosphonate treatment in high-risk elderly patients (older than 70 years), the bone mineral density increase with bisphosphonates accounts for less than 50% of the e ect on fractures.4 Thus, the absence of a positive relation between vitamin D supplementation and change in bone mineral density
could be dismissed as the ndings having few clinical Published Onlineimplications. However, the results are consistent with October 11, 2013
doc.guandang.net
those of two recent meta-analyses of randomised trials S0140-6736(13)61721-3with vitamin D supplementation alone that recorded See Online/Articles
doc.guandang.net
no e cacy in fracture prevention, nor in another meta-S0140-6736(13)61647-5analysis of vitamin D with an intention-to-treat design.5–7Second, it is di cult to distinguish between the e ects of calcium versus those of vitamin D on skeletal integrity, because the main mechanism of action for vitamin D is promotion of calcium absorption in the gut and not direct incorporation of calcium in bone.8 In the present meta-analysis, only half of the trials used both calcium and vitamin D supplementation.1 In trials in which vitamin D was given simultaneously with calcium, a signi cant reduction of 11% in hip fractures and a very modest increase in hip bone mineral density was reported.9,10 This nding formed the basis of the recommendation by the US Institute of Medicine that 1200 mg of calcium and 800 IU of vitamin D were optimum intakes for skeletal health in elderly people.10 The inclusion of more studies with calcium plus vitamin D in the present report could have resulted in greater increases in bone mineral density, but confounding by calcium supplementation would not have clari ed the role of vitamin D alone in supporting bone mass.
Third, mechanisms of vitamin D action on the skeleton have recently been re-examined leading to a new appre-ciation of the vitamin’s biological role; these ndings also
doc.guandang.net Published online October 11, 2013 doc.guandang.net(13)61721-3 1
2013 lancet comments 暂无评价 2页 免费 Lancet Oncol 2013; 14 ... 暂无评价...Lancet Neurol:2013 神经病学总结之多发性硬化医脉通 2013-12-25 发表评论(1 ...
Lancet Neurol:2013神经病学总结之头痛_临床医学_医药卫生_专业资料。Lancet Neurol...神经病学考试重点总结 5页 免费 2013 lancet comments 暂无评价 2页 免费喜欢...
Lancet Neurol:2013 神经病学总结之脑部感染医脉通 2014-01-03 发表评论 分享 脑部感染持续使人们付出沉重的代价,尤其是对于预防、诊断和治疗资源缺乏的人们。 解决...
2013年的SCI杂志分区表_天文/地理_自然科学_专业资料。Abbreviated Journal Title...LANCET NEUROL NAT BIOTECHNOL LANCET ONCOL NAT MED ANNU REV GENET ACCOUNTS ...
2013年度SCI影响因子(IF)-JCR官网2013年6月19日公布_自然科学_专业资料。JCR ...LANCET 0140-6736 166922 39.06 NATURE 0028-0836 554745 38.597 NAT REV ...
LANCET 0140-6736 166922 39.06 NATURE 0028-0836 554745 38.597 NAT REV ...2013 WIRES CLIM CHANGE 1757-7780 CLIN EXP METASTAS 0262-0898 J TRANSL MED...
LANCET 0140-6736 166922 39.06 NATURE 0028-0836 554745 38.597 NAT REV ...2013 WIRES CLIM CHANGE 1757-7780 CLIN EXP METASTAS 0262-0898 J TRANSL MED...
LANCET 0140-6736 166922 39.06 NATURE 0028-0836 554745 38.597 NAT REV ...2013 WIRES CLIM CHANGE 1757-7780 CLIN EXP METASTAS 0262-0898 J TRANSL MED...
2013年度SCI影响因子(IF)_化学_自然科学_专业资料。Rank Abbreviated Journal Title...LANCET 0140-6736 166922 39.06 NATURE 0028-0836 554745 38.597 NAT REV ...
2013年所有SCI杂志JCR分区表-全部学科(完整版)-EXCEL格式_临床医学_医药卫生_专业...LANCET ONCOLOGY Annual Review of PathologyMechanisms of Disease ANNALS OF ...
热门文档